2019
SK biopharmaceuticals Becomes First Korean Company to Receive U.S. FDA Approval for New Drug
SK biopharmaceuticals becomes the first Korean company to independently bring a compound from drug discovery to approval by the U.S. Food and Drug Administration (FDA). The compound, Cenobamate, will be sold as Xcopri for the treatment of partial-onset seizures in adults. SK biopharmaceuticals seeks to further expand its U.S. workforce to support the launch of Xcopri, the company's first commercial product.
